CRISPR/Cas9‐mediated mutagenesis to validate the synergy between PARP1 inhibition and chemotherapy in BRCA1‐mutated breast cancer cells

For patients carrying BRCA1 mutations, at least one‐third develop triple negative breast cancer (TNBC). Not only is TNBC difficult to treat due to the lack of molecular target receptors, but BRCA1 mutations (BRCA1m) also result in chemotherapeutic resistance, making disease recurrence more likely. A...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Bioeng Transl Med
Main Authors: Mintz, Rachel L., Lao, Yeh‐Hsing, Chi, Chun‐Wei, He, Siyu, Li, Mingqiang, Quek, Chai Hoon, Shao, Dan, Chen, Boyuan, Han, Jing, Wang, Sihong, Leong, Kam W.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2020
Assuntos:
Rapid Communication
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6971465/
https://ncbi.nlm.nih.gov/pubmed/31989039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/btm2.10152
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados